Explore this Website
I am interested in...
Wayfinder menu
2025
2024
2023
Michaelson NMiriam, Watsula A, Bakare-Okpala A, Mohamadpour M, Chukwueke UN, Budhu JA .
2023. Disparities in Neuro-Oncology. . Curr Neurol Neurosci Rep.
Williams MJ, Okai AF, Cross AH, Monson NL, Vartanian T, Thrower BW, Reder AT, English JB, Wu GF, Bernitsas E et al. .
2023. Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. . Mult Scler Relat Disord. 76:104794.
2022
Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ .
2022. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. . CNS Drugs. 36(9):977-993.
2021
Lavette LE, Miller A, Rook B, London Z, Cook C, Merkler AE, Santini V, Ruff IMarie, Kraakevik J, Smith D et al. .
2021. Education Research: NeuroBytes: A New Rapid, High-Yield e-Learning Platform for Continuing Professional Development in Neurology. . Neurology. 97(8):393-400.
Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D et al. .
2021. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. . Adv Ther. 38(7):3724-3742.
2020
2019
Cheung JW, Cheng EP, Wu X, Yeo I, Christos PJ, Kamel H, Markowitz SM, Liu CF, Thomas G, Ip JE et al. .
2019. Sex-based differences in outcomes, 30-day readmissions, and costs following catheter ablation of atrial fibrillation: the United States Nationwide Readmissions Database 2010-14. . Eur Heart J. 40(36):3035-3043.
Guo H, Kommidi H, Maachani UB, Voronina JC, Zhang W, Magge RS, Ivanidze J, Wu AP, Souweidane MM, Aras O et al. .
2019. An [18F]-Positron Emitting Fluorophore Allows Safe Evaluation of Small Molecule Distribution in the CSF, CSF Fistulas, and CNS Device Placement. . Mol Pharm. 16(8):3636-3646.
Sandrone S, Berthaud JV, Carlson C, Cios J, Dixit N, Farheen A, Kraker J, Owens JWM, Patino G, Sarva H et al. .
2019. Education Research: Flipped classroom in neurology: Principles, practices, and perspectives. . Neurology. 93(1):e106-e111.
Ramasamy S, Yaghi S, Omran SSalehi, Lerario MP, Devereux R, Okin PM, Gupta A, Navi BB, Kamel H, Merkler AE .
2019. Association Between Left Ventricular Ejection Fraction, Wall Motion Abnormality, and Embolic Stroke of Undetermined Source. . J Am Heart Assoc. 8(9):e011593.
2018
Pillai RLI, Malhotra A, Rupert DD, Weschler B, Williams JC, Zhang M, Yang J, J Mann J, Oquendo MA, Parsey RV et al. .
2018. Relations between cortical thickness, serotonin 1A receptor binding, and structural connectivity: A multimodal imaging study. . Hum Brain Mapp. 39(2):1043-1055.
2017
2016
Zhang Y, Gauthier SA, Gupta A, Chen W, Comunale J, Chiang GC-Y, Zhou D, Askin G, Zhu W, Pitt D et al. .
2016. Quantitative Susceptibility Mapping and R2* Measured Changes during White Matter Lesion Development in Multiple Sclerosis: Myelin Breakdown, Myelin Debris Degradation and Removal, and Iron Accumulation. . AJNR Am J Neuroradiol. 37(9):1629-35.
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R et al. .
2016. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. . Contemp Clin Trials. 50:166-77.
2015
2014
Isaacson RS, Haynes N, Seifan A, Larsen D, Christiansen S, Berger JC, Safdieh JE, Lunde AM, Luo A, Kramps M et al. .
2014. Alzheimer's Prevention Education: If We Build It, Will They Come? www.AlzU.org. J Prev Alzheimers Dis. 1(2):91-98.
2013
2012
1992
1987
1986
1984
1983
1982
1981
1980
1979
1978
1977
1976
1975
1974
1973
1972
1971
1970
1967